| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 07/25/2002 | CA2430589A1 Helper virus-free herpes virus amplicon particles and uses thereof |
| 07/24/2002 | EP1225224A1 Shear stress-response dna |
| 07/24/2002 | EP1225223A1 p21Cip1 REMEDIES FOR RHEUMATISM |
| 07/24/2002 | EP1225222A1 Novel tumor suppressor gene |
| 07/24/2002 | EP1225183A2 Human G-protein coupled receptor |
| 07/24/2002 | EP1224471A2 Dpi-6, a therapeutic biomarker in neurological disorders |
| 07/24/2002 | EP1224461A2 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| 07/24/2002 | EP1224333A2 Methods and compositions for correlating ccr5 expression with essential hypertension |
| 07/24/2002 | EP1224314A2 Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna |
| 07/24/2002 | EP1224313A1 Adeno-associated viruses and uses thereof |
| 07/24/2002 | EP1224312A1 Adeno-associated virus vectors encoding factor viii and methods of using the same |
| 07/24/2002 | EP1224311A1 Recombinant, replication defective celo virus and celo virus dna |
| 07/24/2002 | EP1224305A2 Self-cleaving rna sequences and their use for the control of protein synthesis |
| 07/24/2002 | EP1224302A2 Modified viral surface proteins which bind to cells of tumor vasculature |
| 07/24/2002 | EP1224301A2 Methods and compositions for targeting a cell |
| 07/24/2002 | EP1224291A1 Multiple sclerosis-related superantigen |
| 07/24/2002 | EP1224288A2 Processed human chemokines phc-1 and phc-2 |
| 07/24/2002 | EP1224283A2 Human and rat fgf-20 genes and gene expression products |
| 07/24/2002 | EP1224282A2 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 07/24/2002 | EP1224281A1 37 human secreted proteins |
| 07/24/2002 | EP1224280A2 Design of high affinity rnase h recruiting oligonucleotide |
| 07/24/2002 | EP1224274A1 Tumor necrosis factor related receptor, tr6 |
| 07/24/2002 | EP1224271A1 Expression of recombinant mature lysostaphin |
| 07/24/2002 | EP1224268A1 Methods for using 22045, a human cyclic nucleotide phosphodiesterase |
| 07/24/2002 | EP1224220A2 Epo primary response gene 1, eprg1 |
| 07/24/2002 | EP1224209A1 10 human secreted proteins |
| 07/24/2002 | EP1224203A2 Antisense modulation of protein kinase c-theta expression |
| 07/24/2002 | EP1224202A1 Antisense modulation of integrin-linked kinase expression |
| 07/24/2002 | EP1224201A1 32 human secreted proteins |
| 07/24/2002 | EP1224200A1 Tissue plasminogen activator-like protease |
| 07/24/2002 | EP1223988A1 Antisense modulation of tumor necrosis factor alpha converting enzyme (tace) expression |
| 07/24/2002 | EP1223980A2 Use of csf-1 inhibitors |
| 07/24/2002 | EP1223979A1 Adjuvants for nucleic acid vaccines |
| 07/24/2002 | EP1223977A2 Modified plant viruses and methods of use thereof |
| 07/24/2002 | EP1223974A2 Medicament in order to induce tolerance |
| 07/24/2002 | EP1223966A2 Use of gdnf for treating corneal defects |
| 07/24/2002 | EP1223965A2 Modulation of angiogenesis |
| 07/24/2002 | EP1223963A2 T-cells and molecules involved in immune regulation |
| 07/24/2002 | EP1223961A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
| 07/24/2002 | EP1223953A1 Matrix-targeted fusion polypeptides for tissue regeneration and wound healing |
| 07/24/2002 | EP1223952A2 Methods for treatment of solid tumors and metastasis by gene therapy |
| 07/24/2002 | EP1223950A2 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 07/24/2002 | EP1223947A1 Targeted vectors |
| 07/24/2002 | EP1223946A1 Human neuropeptide receptor |
| 07/24/2002 | EP1223930A1 Treatment of dyskinesia |
| 07/24/2002 | EP1223916A2 Neutral-cationic lipid for nucleic acid and drug delivery |
| 07/24/2002 | EP0800579B1 Combination gene delivery vehicles |
| 07/24/2002 | EP0687184B1 Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases |
| 07/24/2002 | EP0664832B1 Remyelination using neural stem cells |
| 07/24/2002 | CN1360678A Early detection of flaviviruses using NS1 glycoprotein |
| 07/24/2002 | CN1360638A Recombinant protein production in human cell using sequences encoding adenovirus E1 protein |
| 07/24/2002 | CN1360629A Induction of vascular endothelial growth factor (VEGF) by serine/threonine protein kinase AKT |
| 07/24/2002 | CN1360594A Attenuated microorganisms for treatment of infection |
| 07/24/2002 | CN1360507A Conjugates and method for production thereof, and their use for transporting molecules via biological membranes |
| 07/24/2002 | CN1360053A Efficient expression vector of human and mammalion cells |
| 07/23/2002 | US6423824 Cd2 associated intracellular polypeptide capable of binding to intracellular domain |
| 07/23/2002 | US6423693 Growth hormone releasing hormone expression system and methods of use, including use in animals |
| 07/23/2002 | US6423692 Transducing a target cell with a nucleic acid sequence encoding a dck protein (deoxycytidine kinase) having phosphorylation activity operably linked to a promoter |
| 07/23/2002 | US6423544 Compositions and methods for producing recombinant virions |
| 07/23/2002 | US6423527 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 07/23/2002 | US6423516 Process and agent for instabilizing viral quasi-species-distributions avoiding resistance phenomena |
| 07/23/2002 | US6423507 Detecting enzyme inhibitors; obtain protease, incubate with modulator, monitor adjustment in protease activity |
| 07/23/2002 | US6423496 Nucleotide sequences for use in the detection, diagnosis and monitoring of mammary gland tumors |
| 07/23/2002 | US6423316 Anticoagulant fusion protein anchored to cell membrane |
| 07/23/2002 | US6423308 Treatment of Kaposi's sarcoma with IL-12 |
| 07/23/2002 | CA2365997A1 Novel polypeptide |
| 07/23/2002 | CA2074720C Immune reactivity to expressed activated oncogenes for diagnosis and treatment of malignancy |
| 07/23/2002 | CA2072642C Fusion proteins consisting of a ligand binding protein and a stable plasma protein |
| 07/18/2002 | WO2002056027A2 Regulation of neutral development by daedalos |
| 07/18/2002 | WO2002055721A2 Modular transfection systems based on nucleoprotein filaments |
| 07/18/2002 | WO2002055700A2 Human genes and gene expression products isolated from human prostate |
| 07/18/2002 | WO2002055698A2 Transcriptional mediators of blood vessel development and endothelial differentiation |
| 07/18/2002 | WO2002055697A2 Human rhinovirus assays, and compositions comprising anti-rhinoviral perturbagens |
| 07/18/2002 | WO2002055694A2 Discriminative nucleic acid analysis using clone sequence signatures |
| 07/18/2002 | WO2002055693A2 Method for inhibiting the expression of a target gene |
| 07/18/2002 | WO2002055692A2 Method for inhibiting the expression of a target gene and medicament for treating a tumor disease |
| 07/18/2002 | WO2002055691A1 Gene encoding aip-1/flash promoter and use thereof |
| 07/18/2002 | WO2002055678A1 Extramedullary adipose tissue cells and use thereof for regenerating hematopoietic and muscular tissues |
| 07/18/2002 | WO2002055663A2 Srebp pathway modulation through targeting hisrs |
| 07/18/2002 | WO2002055656A2 GENE THERAPY USING TGF-$g(b) |
| 07/18/2002 | WO2002055559A1 Dna vaccines expressing hypervariable vh-cdr3 idiotipic determinants |
| 07/18/2002 | WO2002055556A2 Regulation of human voltage gated potassium channel protein kv2.2 |
| 07/18/2002 | WO2002055535A2 Antisense modulation of cytohesin-1 expression |
| 07/18/2002 | WO2002055110A2 Methods for treating blood coagulation disorders |
| 07/18/2002 | WO2002055109A2 Generation and/or reduction of new lung tissue in an affected lung, by modulation of the wnt-pathway |
| 07/18/2002 | WO2002055108A1 Targeted modification of intracellular compounds |
| 07/18/2002 | WO2002055100A2 Method and composition for inhibition of tumor growth and enhancing an immune response |
| 07/18/2002 | WO2002055098A2 Latency associated peptide for providing latency to pharmaceutically active proteins |
| 07/18/2002 | WO2002055065A2 Use of an ltb4 antagonist for the treatment and/or prevention of diseases caused by increased expression of mucin genes |
| 07/18/2002 | WO2002055010A2 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 07/18/2002 | WO2002054851A2 Inhibition of pathological angiogenesis in vivo |
| 07/18/2002 | WO2002048349A8 Polypeptide capable of binding to heparin |
| 07/18/2002 | WO2002044382A8 Cytokine-like proteins |
| 07/18/2002 | WO2002034280A3 Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain |
| 07/18/2002 | WO2002031025A3 Biodegradable poly(beta-amino esters) and uses thereof |
| 07/18/2002 | WO2002029088A3 Highly expressible genes |
| 07/18/2002 | WO2002029011A3 Use of a composition with antioxidant activity for conditioning stem cells |
| 07/18/2002 | WO2002028418B1 Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
| 07/18/2002 | WO2002028414B1 Compositions and methods for wt1 specific immunotherapy |
| 07/18/2002 | WO2002016549A3 METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE |